Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Symphogen has reported that the European Patent Office granted the company European patent, which describes a high-throughput method for isolating fully human, antigen-specific antibodies directly from human donors, and other related methods.
Subscribe to our email newsletter
The patent covers Symplex, Symphogen’s proprietary process for discovering antibodies with diversity and specificity customized to a particular therapeutic application. The granted European patent is effective in 33 countries across Europe. Symphogen has additional pending applications from this patent in numerous countries across the world.
Kirsten Drejer, CEO of Symphogen, said: “The grant of this European patent for Symplex protects a key commercial asset of the company. Symplex not only fuels our own internal pipeline of antibody therapeutics, but is also available for licensing to companies seeking a powerful antibody discovery tool.”